Neogen Corporation (NASDAQ:NEOG) on Wednesday initiated a voluntary nationwide recall of all unexpired lots of its Neogen Vet HYCOAT Hyaluronate Sodium Sterile Solution. The company identified microbial contamination in certain batches.
The product, used for topical wound management, is distributed to veterinarians and intended for dogs, cats, and horses.
The recall covers HYCOAT 10 mL/50 mg vials manufactured by a third-party supplier, after contamination was detected in some lots. Neogen said it has received several adverse event reports in horses following intra-articular injections — a use inconsistent with the product's labeling — but reported no adverse events when the product was used as directed.
As a precaution, Neogen is also recalling all unexpired lots of the 2 mL/20 mg vials. The company warned that affected products should no longer be considered sterile and could pose an infection risk, particularly if injected into joints, as well as when used topically in surgical wounds, burns, ulcers, and autograft procedures.
Separately, Neogen reported second-quarter 2026 adjusted earnings of 10 cents per share in January. It beat estimates of 6 cents. Revenue totaled $224.69 million, down 2.8% year over year but above consensus of $207.85 million, with core revenue rising 2.9%. The company raised its fiscal 2026 sales forecast to $845 million–$855 million, up from prior guidance of $820 million-$840 million.
Price Action: NEOG stock is down 2.80% at $10.06 at the last check on Thursday, according to Benzinga Pro data.
Image: Shutterstock
